ENT Liu Knowledge Base Head & neck tumours · physician reviewed
Laryngeal Cancer · Prognosis & follow-up

What is the prognosis for laryngeal cancer?

Reviewed: 8 November 2026 By: Xiangpeng Liu, MD Topic: Laryngeal Cancer Answer length: short, citable
Quick answer

Early glottic cancer has excellent control: single-modality treatment is associated with roughly 70–90% five-year survival in guideline summaries, and many patients keep a serviceable voice. Overall global five-year survival is around 60%, falling sharply for advanced T4, node-positive or metastatic disease. Continuing to smoke after treatment increases recurrence and second-primary risk.

In detail

Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment.

Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance.

What this means in practice: this answer is part of the “Prognosis & follow-up” section of the Laryngeal Cancer topic. If you are comparing treatment options, also read how to compare a second opinion and which records to send.

Other common questions about laryngeal cancer

See all 14 questions in this topic →

Sources for this answer

  1. NCCN Guidelines for Patients: Head and Neck Cancers National Comprehensive Cancer Network · 2025
  2. Global Cancer Observatory (GLOBOCAN 2022) International Agency for Research on Cancer / WHO · 2022 · Source of worldwide and country-level incidence and mortality estimates.
  3. Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) American Cancer Society · 2024
  4. Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) European Medicines Agency · 2025 · Reports the combined 947,211 head and neck cancer cases in 2022 and regional ASRs.
  5. Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) Japanese Journal of Clinical Oncology / registry-based review · 2025

Written and medically reviewed by Xiangpeng Liu, MD

Associate Chief Physician, ENT & Head/Neck Surgery · Chenzhou First People’s Hospital, Chenzhou, Hunan, China

Editorial policy & reviewer credentials · All sources

← Previous questionWhat are the treatment options for laryngeal cancer? Next question →Can laryngeal cancer be prevented?

Need an opinion on your own case?

International patients can request a preliminary review based on pathology and imaging before travelling to China.

How the pathway works Send an enquiry

Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.